JP2022169504A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022169504A5 JP2022169504A5 JP2022112873A JP2022112873A JP2022169504A5 JP 2022169504 A5 JP2022169504 A5 JP 2022169504A5 JP 2022112873 A JP2022112873 A JP 2022112873A JP 2022112873 A JP2022112873 A JP 2022112873A JP 2022169504 A5 JP2022169504 A5 JP 2022169504A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 89
- 101150036449 SIRPA gene Proteins 0.000 claims 48
- 239000000427 antigen Substances 0.000 claims 38
- 108091007433 antigens Proteins 0.000 claims 38
- 102000036639 antigens Human genes 0.000 claims 38
- 239000012634 fragment Substances 0.000 claims 36
- 238000000034 method Methods 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 102000044459 human CD47 Human genes 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 238000000338 in vitro Methods 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 238000002405 diagnostic procedure Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 108091008875 B cell receptors Proteins 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims 1
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims 1
- 102100034980 ICOS ligand Human genes 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000008601 Polycythemia Diseases 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 230000003044 adaptive effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000001565 modulated differential scanning calorimetry Methods 0.000 claims 1
- 210000000066 myeloid cell Anatomy 0.000 claims 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000006041 probiotic Substances 0.000 claims 1
- 235000018291 probiotics Nutrition 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 238000011002 quantification Methods 0.000 claims 1
- 230000003439 radiotherapeutic effect Effects 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322707P | 2016-04-14 | 2016-04-14 | |
| US62/322,707 | 2016-04-14 | ||
| EP17305182.2 | 2017-02-17 | ||
| EP17305182 | 2017-02-17 | ||
| PCT/EP2017/059071 WO2017178653A2 (en) | 2016-04-14 | 2017-04-14 | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS |
| JP2018550322A JP7491666B2 (ja) | 2016-04-14 | 2017-04-14 | 新規な抗ＳＩＲＰａ抗体およびそれらの治療適用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018550322A Division JP7491666B2 (ja) | 2016-04-14 | 2017-04-14 | 新規な抗ＳＩＲＰａ抗体およびそれらの治療適用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022169504A JP2022169504A (ja) | 2022-11-09 |
| JP2022169504A5 true JP2022169504A5 (OSRAM) | 2023-02-20 |
| JP7549626B2 JP7549626B2 (ja) | 2024-09-11 |
Family
ID=65529144
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018550322A Active JP7491666B2 (ja) | 2016-04-14 | 2017-04-14 | 新規な抗ＳＩＲＰａ抗体およびそれらの治療適用 |
| JP2022112873A Active JP7549626B2 (ja) | 2016-04-14 | 2022-07-14 | 新規な抗ＳＩＲＰａ抗体およびそれらの治療適用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018550322A Active JP7491666B2 (ja) | 2016-04-14 | 2017-04-14 | 新規な抗ＳＩＲＰａ抗体およびそれらの治療適用 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11279766B2 (OSRAM) |
| EP (1) | EP4438626A3 (OSRAM) |
| JP (2) | JP7491666B2 (OSRAM) |
| KR (1) | KR102355240B1 (OSRAM) |
| CN (1) | CN115785272A (OSRAM) |
| CL (1) | CL2018002898A1 (OSRAM) |
| DK (1) | DK3443010T3 (OSRAM) |
| ES (1) | ES2990971T3 (OSRAM) |
| FI (1) | FI3443010T3 (OSRAM) |
| HR (1) | HRP20241316T1 (OSRAM) |
| HU (1) | HUE068840T2 (OSRAM) |
| IL (1) | IL262251B2 (OSRAM) |
| LT (1) | LT3443010T (OSRAM) |
| MA (1) | MA44665B1 (OSRAM) |
| MD (1) | MD3443010T2 (OSRAM) |
| MX (1) | MX2018012434A (OSRAM) |
| PH (1) | PH12018550160B1 (OSRAM) |
| PL (1) | PL3443010T3 (OSRAM) |
| RS (1) | RS66062B1 (OSRAM) |
| SA (1) | SA518400237B1 (OSRAM) |
| SI (1) | SI3443010T1 (OSRAM) |
| SM (1) | SMT202400438T1 (OSRAM) |
| UA (1) | UA126658C2 (OSRAM) |
| ZA (1) | ZA201806293B (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2990971T3 (es) * | 2016-04-14 | 2024-12-02 | Ose Immunotherapeutics | Nuevos anticuerpos anti-SIRPa y sus aplicaciones terapéuticas |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| AU2018308364C1 (en) * | 2017-07-26 | 2023-02-16 | Forty Seven, LLC | Anti-SIRP-alpha antibodies and related methods |
| US11713356B2 (en) | 2017-10-13 | 2023-08-01 | Ose Immunotherapeutics | Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer |
| WO2019175218A1 (en) | 2018-03-13 | 2019-09-19 | Ose Immunotherapeutics | Use of anti-human sirpa v1 antibodies and method for producing anti-sirpa v1 antibodies |
| US11292850B2 (en) | 2018-03-21 | 2022-04-05 | ALX Oncology Inc. | Antibodies against signal-regulatory protein α and methods of use |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| AU2019349651B2 (en) | 2018-09-27 | 2023-12-07 | Celgene Corporation | SIRP alpha binding proteins and methods of use thereof |
| EP4045083B1 (en) | 2019-10-18 | 2024-01-10 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| NZ786589A (en) | 2019-10-31 | 2025-03-28 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| CN112574310B (zh) * | 2020-12-11 | 2023-05-05 | 浙江博锐生物制药有限公司 | 抗SIRPα抗体及其用途 |
| KR102896511B1 (ko) * | 2022-09-07 | 2025-12-08 | 주식회사 시프트바이오 | SIRPα 변이체에 특이적으로 결합하는 항체 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| WO2001040307A1 (de) | 1999-11-30 | 2001-06-07 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Antikörper gegen signal-regulator-proteine |
| US8613922B2 (en) | 2003-04-24 | 2013-12-24 | The University Of North Carolina At Chapel Hill | Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP) |
| US20100215640A1 (en) * | 2003-04-24 | 2010-08-26 | The University Of North Carolina At Chapel Hill | Method for inhibiting cellular activation by insulin-like growth factor-1 |
| JP3936673B2 (ja) * | 2003-06-02 | 2007-06-27 | 国立大学法人群馬大学 | Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体 |
| KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| EP1930342B1 (en) | 2006-12-04 | 2012-01-25 | Institut Pasteur | OB-fold used as scaffold for engineering new specific binders |
| JP2011500005A (ja) | 2007-10-11 | 2011-01-06 | ユニバーシティー ヘルス ネットワーク | ヒト造血幹細胞の生着を増加させるためのＳＩＲＰα−ＣＤ４７相互作用の調節およびそのための化合物 |
| MX350501B (es) | 2007-10-12 | 2017-09-07 | Massachusetts Inst Technology | Nanotecnologia de vacuna. |
| ES2735144T3 (es) | 2008-01-15 | 2019-12-16 | Univ Leland Stanford Junior | Métodos para manipular fagocitosis mediada por CD47 |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| TWI729512B (zh) | 2008-12-09 | 2021-06-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| CA2761438C (en) | 2009-05-15 | 2017-12-12 | University Health Network | Compositions and methods for treating hematologic cancers targeting the sirp.alpha.-cd47 interaction |
| GB201015765D0 (en) | 2010-09-21 | 2010-10-27 | Immatics Biotechnologies Gmbh | Use of myeloid cell biomarkers for the diagnosis of cancer |
| CN109517897A (zh) | 2011-04-28 | 2019-03-26 | 南加利福尼亚大学 | 人类髓源抑制性细胞癌症标记 |
| MX2013014789A (es) * | 2011-06-16 | 2014-01-20 | Novartis Ag | Proteinas solubles para utilizarse como productos terapeuticos. |
| US20140242095A1 (en) * | 2011-10-19 | 2014-08-28 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| SMT202000689T1 (it) | 2012-01-17 | 2021-01-05 | Univ Leland Stanford Junior | Reagenti per sirp-alfa ad alta affinita' |
| CN105101997B (zh) | 2013-02-06 | 2018-11-09 | 印希彼有限合伙公司 | 不减少血小板和不减少血红细胞的cd47抗体及其使用方法 |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| EP3116544A4 (en) * | 2014-03-11 | 2017-08-23 | The Board of Trustees of the Leland Stanford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| CN105085679B (zh) * | 2014-04-25 | 2019-01-11 | 上海津曼特生物科技有限公司 | 全人源抗rankl抗体 |
| EP3012271A1 (en) | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| WO2016205042A1 (en) | 2015-06-16 | 2016-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | SIRPα AGONIST ANTIBODY |
| ES3032613T3 (en) | 2015-10-21 | 2025-07-22 | Ose Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
| ES2990971T3 (es) * | 2016-04-14 | 2024-12-02 | Ose Immunotherapeutics | Nuevos anticuerpos anti-SIRPa y sus aplicaciones terapéuticas |
| EP3443010B1 (en) | 2016-04-14 | 2024-08-07 | Ose Immunotherapeutics | New anti-sirpa antibodies and their therapeutic applications |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| US11779642B2 (en) | 2016-12-09 | 2023-10-10 | Alector Llc | Anti-SIRP-alpha antibodies and methods of use thereof |
| SG11201908813QA (en) * | 2017-04-13 | 2019-10-30 | Aduro Biotech Holdings Europe B V | Anti-sirp alpha antibodies |
| US11274159B2 (en) | 2017-05-16 | 2022-03-15 | Byondis B.V. | Anti-SIRPα antibodies |
| AU2018308364C1 (en) | 2017-07-26 | 2023-02-16 | Forty Seven, LLC | Anti-SIRP-alpha antibodies and related methods |
| US11713356B2 (en) | 2017-10-13 | 2023-08-01 | Ose Immunotherapeutics | Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer |
| WO2019175218A1 (en) | 2018-03-13 | 2019-09-19 | Ose Immunotherapeutics | Use of anti-human sirpa v1 antibodies and method for producing anti-sirpa v1 antibodies |
| US11292850B2 (en) | 2018-03-21 | 2022-04-05 | ALX Oncology Inc. | Antibodies against signal-regulatory protein α and methods of use |
| JP7337099B2 (ja) | 2018-05-25 | 2023-09-01 | アレクトル エルエルシー | 抗ｓｉｒｐａ抗体およびその使用法 |
| WO2020013170A1 (ja) | 2018-07-10 | 2020-01-16 | 国立大学法人神戸大学 | 抗ＳＩＲＰα抗体 |
| WO2020033646A1 (en) | 2018-08-08 | 2020-02-13 | Orionis Biosciences, Inc. | SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF |
| AU2019349651B2 (en) | 2018-09-27 | 2023-12-07 | Celgene Corporation | SIRP alpha binding proteins and methods of use thereof |
| BR112021009325A2 (pt) | 2018-11-14 | 2021-09-14 | Arch Oncology, Inc. | Anticorpo monoclonal, ou fragmento de ligação ao antígeno do mesmo; anticorpo biespecífico; método para prevenir ou tratar um câncer suscetível em um ser humano; método de ensaio de expressão de sirp¿ em células tumorais e/ou imunes; e; composição farmacêutica |
| JP7451520B2 (ja) | 2018-11-15 | 2024-03-18 | ビョンディス・ビー．ブイ． | ヒト化抗ＳＩＲＰα抗体 |
| US20220235144A1 (en) | 2019-03-04 | 2022-07-28 | Qilu Puget Sound Biotherapeutics Corporation | Anti-sirp-alpha antibodies |
| AU2020286285A1 (en) | 2019-08-20 | 2021-03-11 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel anti-SIRPa antibodies |
| CN111635458A (zh) | 2020-03-20 | 2020-09-08 | 上海健信生物医药科技有限公司 | 靶向Sirpα的抗体或其抗原结合片段及其制备和应用 |
| CN112010979B (zh) | 2020-08-21 | 2022-05-10 | 博奥信生物技术（南京）有限公司 | 一种抗人SIRPα单克隆抗体及其用途 |
| CN111995682B (zh) | 2020-08-21 | 2022-05-10 | 博奥信生物技术（南京）有限公司 | 抗人SIRPα单克隆抗体及其用途 |
| CN112574310B (zh) | 2020-12-11 | 2023-05-05 | 浙江博锐生物制药有限公司 | 抗SIRPα抗体及其用途 |
-
2017
- 2017-04-14 ES ES17718881T patent/ES2990971T3/es active Active
- 2017-04-14 MX MX2018012434A patent/MX2018012434A/es unknown
- 2017-04-14 HR HRP20241316TT patent/HRP20241316T1/hr unknown
- 2017-04-14 IL IL262251A patent/IL262251B2/en unknown
- 2017-04-14 DK DK17718881.0T patent/DK3443010T3/da active
- 2017-04-14 MA MA44665A patent/MA44665B1/fr unknown
- 2017-04-14 UA UAA201809487A patent/UA126658C2/uk unknown
- 2017-04-14 US US16/093,062 patent/US11279766B2/en active Active
- 2017-04-14 JP JP2018550322A patent/JP7491666B2/ja active Active
- 2017-04-14 KR KR1020187032968A patent/KR102355240B1/ko active Active
- 2017-04-14 PL PL17718881.0T patent/PL3443010T3/pl unknown
- 2017-04-14 RS RS20241172A patent/RS66062B1/sr unknown
- 2017-04-14 LT LTEPPCT/EP2017/059071T patent/LT3443010T/lt unknown
- 2017-04-14 CN CN202310060526.8A patent/CN115785272A/zh active Pending
- 2017-04-14 EP EP24190165.1A patent/EP4438626A3/en active Pending
- 2017-04-14 PH PH1/2018/550160A patent/PH12018550160B1/en unknown
- 2017-04-14 SI SI201731557T patent/SI3443010T1/sl unknown
- 2017-04-14 SM SM20240438T patent/SMT202400438T1/it unknown
- 2017-04-14 HU HUE17718881A patent/HUE068840T2/hu unknown
- 2017-04-14 FI FIEP17718881.0T patent/FI3443010T3/fi active
- 2017-04-14 MD MDE20190221T patent/MD3443010T2/ro unknown
-
2018
- 2018-09-19 ZA ZA2018/06293A patent/ZA201806293B/en unknown
- 2018-10-11 CL CL2018002898A patent/CL2018002898A1/es unknown
- 2018-10-14 SA SA518400237A patent/SA518400237B1/ar unknown
-
2022
- 2022-02-25 US US17/681,219 patent/US12252546B2/en active Active
- 2022-07-14 JP JP2022112873A patent/JP7549626B2/ja active Active
-
2025
- 2025-03-11 US US19/076,531 patent/US20250215108A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022169504A5 (OSRAM) | ||
| US11987635B2 (en) | Anti-4-1BB antibodies and methods of making and using thereof | |
| CN109843927B (zh) | 抗b7-h3抗体、其抗原结合片段及其医药用途 | |
| JP2019520034A5 (OSRAM) | ||
| CN116239698A (zh) | 双功能融合蛋白及其医药用途 | |
| CN116693686A (zh) | 抗b7-h4抗体、其抗原结合片段及其医药用途 | |
| CN102753195A (zh) | 用于增强抗肿瘤抗体疗法的方法 | |
| CN112969714A (zh) | 抗cd40抗体、其抗原结合片段及其医药用途 | |
| CN114591434B (zh) | 抗Siglec15抗体及其制备方法和用途 | |
| EP4317186A1 (en) | Nanobody targeting bcma and application thereof | |
| CN115785272A (zh) | 新型抗-SIRPa抗体及其治疗应用 | |
| WO2022143552A1 (zh) | Pd-1结合分子及其应用 | |
| CN109384845B (zh) | 一种cd40单克隆抗体、其制备方法及其应用 | |
| CN112480259B (zh) | 抗tnfr2抗体及其用途 | |
| US20250333508A1 (en) | CTLA-4 Binding Molecule and Use Thereof | |
| CN110461874B (zh) | 抗gitr抗体、其抗原结合片段及其医药用途 | |
| IL307336A (en) | Novel tnfr2 binding molecules | |
| RU2761638C1 (ru) | Антитела против лиганда программируемой смерти (pd-l1) и их применение | |
| CN116444672B (zh) | 人表皮生长因子3的抗体、其制备方法及其应用 | |
| CN111763258A (zh) | 抗ox40抗体及其用途 | |
| EP4403571A1 (en) | Human epidermal growth factor receptor binding molecule and use thereof | |
| JP2024522349A (ja) | Ｃ－ｘ－ｃモチーフケモカイン受容体６（ｃｘｃｒ６）結合分子及びその使用方法 | |
| JPH08509963A (ja) | ＩｇＧ▲下３▼抗体を含む組成物 | |
| TW202144425A (zh) | 特異性抗原結合分子，其製備方法及醫藥用途 | |
| US20240067741A1 (en) | Anti-4-1bb antibodies and methods of making and using thereof |